Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned an average recommendation of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $107.9091.

MNPR has been the topic of several research reports. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Chardan Capital reissued a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a research report on Monday, March 30th. HC Wainwright reissued a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st.

Institutional Trading of Monopar Therapeutics

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter worth $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth $65,000. JPMorgan Chase & Co. lifted its stake in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Monopar Therapeutics in the 2nd quarter worth $80,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $59.77 on Monday. Monopar Therapeutics has a 1-year low of $29.18 and a 1-year high of $105.00. The stock has a market cap of $400.46 million, a P/E ratio of -31.46 and a beta of 1.52. The firm has a fifty day moving average price of $58.71 and a 200 day moving average price of $62.81.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.41. Sell-side analysts expect that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.